Drug Profile

SAT 3247

Alternative Names: SAT-3247

Latest Information Update: 03 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Satellos Bioscience
Class Small molecules
Mechanism of Action Adaptor-associated kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Duchenne muscular dystrophy
New Molecular Entity Yes

Highest Development Phases

Phase I Duchenne muscular dystrophy
Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury

Most Recent Events

22 May 2025 Efficacy and pharmacokinetics data from phase-I trial in Duchenne muscular dystrophy released by Satellos Bioscience
13 May 2025 Satellos Bioscience plans global regulatory filings for Duchenne muscular dystrophy (In children) in Q3 2025
28 Apr 2025 Satellos Bioscience completes the phase 0 for Duchenne muscular dystrophy in Australia (PO) (NCT06565208)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com